查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1136899

2022-2029 年全球急性冠状动脉综合征市场

Global Acute Coronary Syndrome Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

全球急性冠状动脉综合征市场的增长受到多种因素的推动，包括急性冠状动脉综合征患者的激增、慢性病患病率的上升以及高血压、高血压和肥胖病例的上升。 .

全球慢性病患病率上升和技术进步不断推动市场增长。

由于全球不健康的生活方式和环境变化，心力衰竭、心血管疾病和冠状动脉疾病等慢性疾病的患病率不断上升，这正在推动市场发展。根据国家健康和营养检查调查 (NHANES) 数据 (2020)，估计有 620 万美国 20 岁及以上成年人 (2.2%) 患有心力衰竭。超过 570 万美国人患有心力衰竭，每年诊断出大约 915,000 例新病例。对于晚期心力衰竭患者，心室辅助装置将血液泵入全身以支持虚弱的心臟。

根据美国心臟协会 2022 年报告，在社会经济条件较差的诊所接受治疗的冠状动脉疾病（服务费）的医疗保险患者因不稳定型心绞痛住院的风险增加。事实证明。因此，这些冠状动脉疾病正在增加，导致急性冠状动脉市场的增长。

治疗急性冠状动脉综合征的技术进步也在推动全球心臟辅助设备的增长。例如，2021 年 6 月，雅培宣布它可以支持对机械循环支持设备不断增长的需求，以充分治疗晚期心力衰竭。

与治疗急性冠状动脉综合征相关的高成本将阻碍市场增长。

然而，在亚洲等价格敏感地区，急性冠状动脉综合征药物的高成本可能会影响市场。在这些地区，患者和医生更喜欢更便宜的治疗和手术。急性冠状动脉综合征的药物价格昂贵。这是急性冠状动脉综合征市场增长面临的主要全球挑战之一。

COVID-19 影响分析

大流行还导致供应链中断，影响全球医疗产品市场。大流行正在对全球金融预期、供应链、运营、危机应对策略等产生负面影响。由于 COVID-19 的传播导致关闭和旅行限制，新兴急性冠状动脉综合征药物的製造商面临挑战。由于 COVID-19 感染的传播对主要经济体产生了重大影响，急性冠状动脉综合征药物的生产受到了很大影响。

市场参与者正在改变他们的长期和短期增长战略，利用研究市场和创造尖端产品来抗击这一流行病。即使 COVID-19 损害了急性冠状动脉综合征行业，重要的是要尽快为业务运营製定备用计划。

您将可以访问全球急性冠状动脉综合征市场报告中大约 40 多个市场数据表、45 多个数字和 200 页（大约）。

内容

第一章市场研究方法和范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 慢性病增加
      • 老年人口增加
    • 约束因素
      • 根治性手术费用高
      • 与心血管设备相关的高价
      • 严格监管
    • 商机
    • 影响分析

第五章行业分析

  • 波特五力分析
  • 供应链分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按类型

  • ST段抬高型心肌梗死
  • 非 ST 段抬高型心肌梗死
  • 不稳定型心绞痛

第8章药物

  • 抗血栓药物
  • 降压药
  • 他汀类药物

第 9 章，最终用户

  • 医院
  • 专科诊所
  • 其他

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准

第 12 章公司简介

  • Teva Pharmaceuticals
    • 公司简介
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Dr. Reddy's Laboratories
  • Boehringer Ingelheim
  • Johnson & Johnson
  • Merck
  • Novartis
  • Amgen Inc.
  • AbbVie Inc.
  • AstraZeneca PLC
  • GlaxoSmithKline Plc

第 13 章全球急性冠状动脉综合征市场-DataM

简介目录
Product Code: DMPH875

Market Overview

Acute Coronary Syndrome Market was valued at US$ 28,992.31 million in 2021 and is estimated to reach US$ 78,626.54 million by 2029, growing at a CAGR of 8.74% during the forecast period (2022-2029).

Acute coronary syndrome (ASC) occurs when a blood clot suddenly forms within a coronary artery, usually due to the acute rupture of an atherosclerotic plaque. The blood clot may produce partial or complete blockage of the artery, placing the heart muscle supplied by that artery in immediate jeopardy.

Market Dynamics

The global acute coronary syndrome market growth is driven by many factors, such as the rapid surge in acute coronary syndrome cases, the rising prevalence of chronic diseases and increasing cases of high blood pressure, hypertension and obesity.

The increasing prevalence of the chronic disease across the globe and rising technological advancements are driving the market growth.

The market is driven by the rising prevalence of chronic ailments like heart failure, cardiovascular disease, and coronary artery disease due to unhealthy lifestyles and changing environments worldwide. According to the National Health and Nutrition Examination Survey (NHANES) data (2020), an estimated 6.2 million American adults ≥20 years of age (2.2%) had heart failure. More than 5.7 million Americans suffer from heart failure, and approximately 915,000 new patients are diagnosed annually. For patients with advanced heart failure, ventricular assist devices support the weakened heart by pumping blood through the body.

According to the American Heart Association report 2022, Medicare patients (service fee) with coronary artery disease who received treatment at socioeconomically impoverished practices were at higher risk of being admitted for unstable angina. Hence these coronary artery diseases are increasing, leading to the growth of the acute coronary market.

Increasing technological advancements in acute coronary syndrome treatment are also fuelling the growth of cardiac assist devices globally. For instance, in Jun 2021, Abbott announced that the company could support the growing demand for mechanical circulatory support devices to treat advanced heart failure properly.

The high cost associated with acute coronary syndrome treatment will hamper the market's growth.

However, in price-sensitive regions such as Asia, the high cost of acute coronary syndrome therapeutics may impact the market. In these areas, patients and doctors prefer less expensive therapies or surgeries. Acute coronary syndrome treatments are expensive. This is one of the major global challenges to the acute coronary syndrome market's growth.

COVID-19 Impact Analysis

The pandemic has also caused supply chain disruptions, impacting the world market for medical products. The pandemic has negatively impacted global financial expectations, supply chains, operations, and crisis response strategies. Due to lockdowns and travel restrictions brought on by the spread of COVID-19, makers of novel acute coronary syndromes treatment experienced problems. Because the spread of COVID-19 infections badly impacted major economies, acute coronary syndrome therapeutics production was greatly impacted.

Market participants are changing their long-term and short-term growth strategies by utilizing the research market and creating cutting-edge items to combat the pandemic. Even though COVID-19 harms the acute coronary syndrome industry, preparing and implementing backup plans as soon as possible for business operations is crucial.

Segment Analysis

The ST-elevation myocardial infarction segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

ST-elevation myocardial infarction shows significant growth, accounting for the largest market share, due to the regulatory approval for ST-elevation myocardial infarction drugs. For instance, in Jun 2020, AstraZeneca announced that Brilinta (ticagrelor) received approval from US Food and Drug Administration. Brilinta is used for reducing first stroke or heart attack risk in patients at high risk with coronary artery disease.

New technological advancements, novel pipelines, and clinical research in acute coronary syndrome treatments will also lead to market growth. For instance, in Aug 2022, AstraZeneca presented its novel results from the analysis of phase III trials of DAPA-HF and DELIVER that shows the mortality benefit of Farxiga over placebo in heart failure patients.

Geographical Analysis

The North American region holds the largest global acute coronary syndrome market.

North America dominates the acute coronary syndrome market and is expected to show a similar trend over the forecast period. The growth of North American acute coronary syndrome can be attributed to the rising prevalence of heart failure cases and the surge in the geriatric population. Strong healthcare infrastructure and an increase in research and development expenditure are to blame for this supremacy.

Furthermore, the rising prevalence of chronic diseases like myocardial infarction, unstable angina, etc., in this region due to unhealthy lifestyles and diets has propelled acute coronary syndrome treatment demand in the market. According to the American Heart Association report 2020, approximately 790,000 people in the U.S. have heart attacks yearly. The rising number of people suffering from cardiovascular diseases and growing technological advancements and mergers or acquisitions by key players boost the demand for acute coronary syndrome treatment in this region. For instance, in Jun 2021, Abiomed announced its acquisition of a precardiac catheter developer that provides less invasive options for treating patients with acute decompensated heart failure.

Competitive Landscape

The acute coronary syndrome market is highly competitive with local and global companies. Some key players contributing to the market's growth are Teva Pharmaceuticals, Dr. Reddy's Laboratories, Boehringer Ingelheim, Johnson & Johnson, Merck, Novartis, Amgen Inc., AbbVie Inc., AstraZeneca PLC and GlaxoSmithKline Plc among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, contributing to the growth of the acute coronary syndrome market globally. For instance, in May 2022, Johnson and Johnson announced that its results from XARELTO (rivaroxaban), combined with the acetylsalicylic acid (XATOA) registry, were published in the European Heart Journal of the European Society of Cardiology. This study supports XARELTO's dual pathway inhibition role in coronary artery disease patients.

In Sep 2022, Abiomed announced that U.S. FDA approved two clinical research Impella heart pumps that can be used in acute myocardial infarction.

Teva Pharmaceuticals.

Overview:

Teva Pharmaceuticals is a multinational pharmaceutical company established in 1901 and headquartered in Tel Aviv, Israel. It specializes in generic drugs (primary), active pharmaceutical ingredients and proprietary pharmaceuticals.

Product Portfolio:

Ranexa: Ranolazine is a medicine used to treat chest pain related to the heart, such as chronic stable angina. It improves the blood flow toward the heart and makes it work efficiently. It can be used in combination with other medicines.

The global acute coronary syndrome market report would provide access to approximately 40+ market data tables, 45+ figures, and 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing prevalence of chronic diseases
      • 4.1.1.2. Growing geriatric population
    • 4.1.2. Restraints:
      • 4.1.2.1. The high cost of therapeutic surgeries
      • 4.1.2.2. High price associated with the cardiovascular devices
      • 4.1.2.3. Stringent regulations
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. ST-Elevation Myocardial Infarction*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Non-ST-Elevation Myocardial Infarction
  • 7.4. Unstable Angina

8. By Drugs

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 8.1.2. Market Attractiveness Index, By Drugs
  • 8.2. Antithrombotic*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Antihypertensive
  • 8.4. Statin Drugs

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospital*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Specialty Clinics
  • 9.4. Other

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Company Profiles

  • 12.1. Teva Pharmaceuticals*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Dr. Reddy's Laboratories
  • 12.3. Boehringer Ingelheim
  • 12.4. Johnson & Johnson
  • 12.5. Merck
  • 12.6. Novartis
  • 12.7. Amgen Inc.
  • 12.8. AbbVie Inc.
  • 12.9. AstraZeneca PLC
  • 12.10. GlaxoSmithKline Plc

LIST NOT EXHAUSTIVE

13. Global Acute Coronary Syndrome Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us